News | November 20, 2007

Influenza Vaccine Supplies Fall Short by More Than 10 Billion Doses Required for a Pandemic

November 21, 2007 - If an influenza pandemic occurred this year, less than one-fifth of the approximately 13 billion vaccine doses needed to fully vaccinate the global population would be available within six months in a best-case scenario, according to a new study released Nov. 20.

It offers evidence of the need to increase the supply of pandemic flu vaccines and develop a global distribution framework. The study identifies both short-term and long-term strategies that should be pursued to maximize protection against pandemic flu for people in all countries.

The study, “Influenza Vaccine Strategies for Broad Global Access,” addresses the next influenza pandemic, which could result in more than 100 million deaths worldwide. It was prepared by the nonprofit global health organization PATH and management consultancy Oliver Wyman, in collaboration with the World Health Organization (WHO). The study presents key information and perspectives related to pandemic vaccine demand and supply from national policymakers, nongovernmental organizations, influenza vaccine manufacturers and developers, and other stakeholders, and suggests new strategies and policies to help meet the global demand for pandemic flu vaccines.

“Preventive measures for influenza are a global priority, given both the current disease burden associated with seasonal strains as well as the potential for significant mortality and morbidity due to an emergent pandemic strain,” explains Dr. Kathryn Edwards, scientific consultant to PATH and vice chair for Pediatric Research at Vanderbilt University. The authors have developed a detailed set of recommendations on how best to provide global access to pandemic vaccines. Findings from this study were shared and discussed at a WHO consultation of global experts on pandemic influenza vaccines in Geneva on Oct. 19.

“While the situation at first glance looks extremely challenging, there are real solutions that can be pursued to close the gap,” said Andrew Pasternak, a director at Oliver Wyman. “Successfully realizing these solutions, however, will require both global commitment and careful coordination among key stakeholders, with WHO playing a central role.”

In the near term, Oliver Wyman and PATH calculate that of the approximately 13 billion doses (to provide coverage with 2 doses of vaccine for the entire world population) needed in case of an outbreak, only 2.4 billion doses could be generated within a six-month time frame under a best-case scenario, given existing vaccine production capacity and the use of inactivated egg-based vaccines. Thus, real-time access, in which vaccine production is begun at the time of the outbreak and is based on the actual pandemic strain, is not a viable approach in the near-term to providing global coverage. Moreover, because most manufacturing capacity is in developed countries, it is unlikely the near-term supply will be available for export to low-resource countries. Without a targeted strategy to stimulate the evolution of industry capacity, it is unlikely the goal of meeting the needs of both industrialized and developing countries by 2012 will be achieved.

In contrast to waiting for a pandemic to start before initiating vaccine production, if pre-pandemic measures, in which production of vaccines based on currently circulating H5N1 strains for stockpiling or pre-pandemic immunization, began today, global demand could be covered by 2011 in a best-case scenario. However, in an alternative scenario, less than 20 percent of the global population would be covered by 2013. “The success of these measures depends on implementing new approaches such as providing broad access to novel, antigen-sparing adjuvants and successfully extending the shelf life of vaccine stockpiles,” notes Adam Sabow, a Principal at Oliver Wyman.

In the longer term, newer technologies including live attenuated (egg-based or cell-based) technology and recombinant technologies (proteins and virus-like particles) have the potential to meet the need for affordable influenza vaccines. Vaccines based on these technologies could potentially be produced for less than 25 cents per dose, the authors estimate.

Using these technologies, four to eight bulk production facilities located in developing countries would result in sufficient surge capacity to serve the vast majority of global populations in the event of an outbreak. Encouragingly, significant fill/finish capacity (the activities for putting formulated bulk vaccine in vials to be distributed) exists globally which could be diverted in the event of an outbreak, provided there is an advance political commitment to quickly implement this if needed.

The study estimates that an investment of $2 billion to $10 billion is required to implement both near-term and longer-term strategies for vaccine access. This takes into account upfront investments to create capacity, and ongoing manufacturing costs during the pre-pandemic and during-pandemic periods, but does not include profit margins for vaccine manufacturers (which need to be determined through specific commercial terms) or overall costs to administer the vaccines. The report details the activities that will need to occur in many sectors to implement these strategies. Successfully executing these activities will require extraordinary collaboration and coordination among WHO, vaccine manufacturers, and developed and developing world policymakers, among others.

For more information: